Mitochondrial myopathies caused by prolonged use of telbivudine
暂无分享,去创建一个
[1] K. Wong,et al. Clinicopathological Features of Telbivudine-Associated Myopathy , 2016, PloS one.
[2] R. Thimme,et al. Natural history of chronic hepatitis B virus infection , 2015, Medical Microbiology and Immunology.
[3] Huiqiong Zhou,et al. Entecavir‐associated myopathy: A case report and literature review , 2014, Muscle & nerve.
[4] Eun Hye Kim,et al. Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B , 2013, Clinical and molecular hepatology.
[5] J. Jia,et al. Telbivudine myopathy in a patient with chronic hepatitis B , 2012, International Journal of Clinical Pharmacy.
[6] X. Zou,et al. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine , 2011, Journal of viral hepatitis.
[7] Dong Kuck Lee,et al. Long‐term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA , 2009, Hepatology.
[8] M. Manns,et al. Trial Results : Telbivudine Is Superior to Lamivudine in atients With Chronic Hepatitis B UN – , 2022 .
[9] Y. Lo,et al. Continuous single motor unit electromyographic activity in adefovir associated myopathy , 2008, Journal of Clinical Neuroscience.
[10] G. Fattovich,et al. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. , 2008, Journal of hepatology.
[11] R. Hamatake,et al. Entecavir for Treatment of Hepatitis B Virus Displays No In Vitro Mitochondrial Toxicity or DNA Polymerase Gamma Inhibition , 2007, Antimicrobial Agents and Chemotherapy.
[12] Ò. Miró,et al. Clinical, histological and molecular reversibility of zidovudine myopathy , 1998, Journal of the Neurological Sciences.
[13] H. Reichmann,et al. Mitochondrial myopathy caused by long-term zidovudine therapy. , 1990, The New England journal of medicine.